The combination of multiple exostoses (EXT) and enlarged parietal foramina (foramina parietalia permagna, FPP) represent the main features of the proximal 11p deletion syndrome (P11pDS), a contiguous gene syndrome (MIM 601224) caused by an interstitial deletion on the short arm of chromosome 11. Here we present clinical aspects of two new P11pDS patients and the clinical follow-up of one patient reported in the original paper describing this syndrome. Recognised clinical signs include EXT, FPP, mental retardation, facial asymmetry, asymmetric calcification of coronary sutures, defective vision (severe myopia, nystagmus, strabismus), skeletal anomalies (small hands and feet, tapering fingers), heart defect, and anal stenosis. In addition fluorescence in situ hybridisation and molecular analysis were performed to gain further insight in potential candidate genes involved in P11pDS.
Introduction
Previously we described a contiguous gene syndrome due to deletions of the proximal short arm of chromosome 11 in eight patients from four families. 1 Initially this syndrome was referred to as DEFECT 11 syndrome, 1 but as this was considered potentially discriminating or offending to the patients and family members the accepted term today is proximal 11p deletion syndrome (P11pDS). 2 Alternatively, Potocki-Shaffer syndrome is also used. In the original patients co-occurence of multiple exostoses (EXT) and foramina parietalia permagna (FPP) were observed, although the latter sign shows reduced penetrance. Additional features observed in a subset of patients included facial dysmorphism and mental retardation (MR). More detailed clinical analysis in recent papers have added additional characteristics of this syndrome, including complex malformations of the brain. 3, 4 All patients have cytogenetic and/or molecular deletions of chromosome 11p11 -p13 located in a B20 cM region between the centromere and D11S914, with the severity of the clinical spectrum being related to the extent of the deletion. 1 Since the original report, review of the literature and additional studies have identified additional patients, but P11pDS remains very rare with less than 20 well described patients. 1,3 -10 Today the genes responsible for the two main characteristics of P11pDS have been identified. The deletion of the EXT2 gene is responsible for the development of multiple exostoses, 6 with EXT2 encoding a glycosyltransferase involved in heparan sulfate biosynthesis. 11 Inactivating mutations in EXT2 also cause multiple exostoses in nonsyndromic patients suffering from isolated hereditary multiple exostoses (HME). 6, 12 The characteristic skull ossification defect (FPP) in P11pDS is the result of the deletion or inactivation of the ALX4 transcription factor, which is located close to and proximal of the EXT2 gene. 13, 14 The role of other genes located within the respective deletion interval of the various patients remains to be elucidated.
Here we present two additional P11pDS patients and provide a clinical follow-up of one previously described patient. Molecular analyses were performed to gain more insight in the position and possible role of further candidate genes for the observed clinical signs and symptoms.
Materials and methods
Cytogenetic analysis and fluorescence in situ hybridisation (FISH) All patients were investigated by conventional karyotyping of cultured lymphocytes from peripheral blood using GTG banding at a 550 þ band level prior to or in this study.
The FISH studies were performed using metaphase spreads from cultured lymphocytes. A total of five different FISH probes (AN-G1, WT1, DO694, 1/IB1, and P5030) were analysed using a protocol described elsewhere. 15 The probes map on chromosome 11 from p13 to the centromere in the given order. 
Results

Clinical analysis
Patient 1 This female patient (Figure 1a , b) was born in 1977 to healthy German parents. Pre-and perinatal history was normal with birth weight 3000 g (P50) and length 52 cm (P90). However, hypotonia and developmental delay became soon evident. At 2.5 years multiple exostoses were diagnosed ( Figure 1c ). She sat without support at age 3 years and walked at age 7 years. Painful exostoses impairing articular function were removed by surgery. She had her menarche at age 11 years and regular bleedings. At 15 years she was referred to one of us (PM) who noted left facial asymmetry, high forehead, brachycephaly, large ears prominent high chin and high myopia at À10 dpt. In addition a small flat nose, and narrow maxilla were observed. There was severe MR with extreme delay of speech development. Following a seizure at age 17 years she was seen again. On physical examination of her skull parietal bone defects measuring 1 -1.5 cm in size were noticed and subsequently the P11pDS was diagnosed. Cranial CT (Figure 1d ) showed asymmetric hyperplasia of calvarial bones, a thickened coronary suture on the right and bilateral parietal foramina. The cerebellar vermis and hemispheres were markedly hypoplastic and the posterior horn of the right lateral ventricle was moderately enlarged. At her last visit at age 21 years her height was measured 160 cm (25oPo50) and her weight was 70 kg (P90). Occipital-frontal circumference (OFW) measured 54 cm (25oPo50). At age 25 years she is clearly obese with a weight of 88 kg.
Patient 2 This girl, born in 1996, is the second child of young nonrelated parents of Albanian extraction.
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Pregnancy and birth at term were uncomplicated. Her birth weight and length were 3280 g (P90) and 51 cm (P75), respectively. By the age of 2 months anal atresia with anal fistula and two small muscular ventricular septal defects were observed. X-ray investigations (arm, hand, and vertebral column) did not show any abnormalities. At age 4 months muscular hypotonia became apparent as well as nystagmus. Length and weight were within normal limits while her head circumference measured 40.1 cm (P25). The occiput appeared flat and there was temporal narrowing, upslant of palpebral fissures, epicanthus, alternating convergent strabismus, horizontal nystagmus, and somewhat large ears (Figure 2a, b) . A 2/6 systolic heart murmur, ventrally placed anus, small hands, and tapering fingers were observed. At age 2 years and 10 months, her height was 93.2 cm (25oPo50) and weight 16.5 kg (90oPo97). OFC measured 46.5 cm (oP3). She showed prominent glabella, full cheeks, narrow nose, hypoplastic alar wings, prominent chin, small teeth. and diastemata between maxillar and manibular incisivi. Her developmental milestones were markedly retarded with beginning to babble and sitting by age 2 years, standing unsupported at 6 years and walking by the age of 6 1 2 years. On re-examination at age 7 years and 2 months, she was 120 cm tall (25oPo50) and her weight was 23 kg (P50). Head circumference was 48.4 cm (oP3). She showed brachycephaly, a medially prominent forehead, narrow pointed nose, large ears, and diastemata. Both forearms showed radial bowing with restricted supination and extension in the right elbow. At both knees exostoses were palpable in the distal portion of the femora and proximal portion of the tibiae (Figure 2c ). There was some restriction of extension in the left knee joint. Toes II/III showed syndactyly. She showed marked muscular hypotonia and slow muscular responses. She had profound MR with absent eye contact and produced chains of two syllables, but no meaningful words. Figure 3 ) has been described previously 1, 17 . Here we report the clinical follow-up. At 14 years he was vital and lived with his mother. Height was approximately 143 cm (oP3), weight 25 kg (oP5), and head circumference 50 cm (oP3). He showed facial dysmorphism, turribrachycephaly, bilateral parietal foramina being 4 cm in diameter, strabismus, frequent fits of nystagmus, severe myopia (À7 to À10 dpt), numerous large painful exostoses and small hands and feet with tapering fingers. He had seizures since the age of 10 years. The psychomotor retardation was profound with a most severe attention deficit and autistic behaviour. He never walked alone, could not sit unsupported and is now wheelchairbound. He could neither eat nor drink by himself and was averbal, even without comprehending his name. He had open eyes but showed no noticeable reaction to visual or acoustic stimuli. The major P11pDS features observed in the three patients are summarised in Cytogenetic and FISH Analysis Patient 1 Initially the karyotype of patient 1 was regarded as normal. After clinically diagnosing the P11pDS, cytogenetic re-examination at 550 bands (GTG) revealed the deletion of bands p11.2 -p11.12 on chromosome 11 (Figure 1e ). FISH analysis showed the deletion at EXT2 and IB1 (Figure 1f ). Parental karyotypes were normal. Her final karyotype read 46,XX,del(11)(p11.2p11.12).ish del (11) 
Patient 3 This male patient (
Patient 2 Standard karyotyping at 550 bands resolution (GTG) revealed the deletion of bands p11.2 -p11.12 on chromosome 11 (Figure 2d ), without the P11pDS suspected on clinical grounds. FISH analysis shows the deletion at EXT2 and IB1 (Figure 2e ). Parental karyotypes were normal. The final karyotype read 46,XX,del(11)(p11.2p11.12).ish del(11)(p11.2p11.2)(WT1 þ ,EXT2À,IB1À,D11Z1 þ ) de novo.
Patient 3 Cytogenetic analysis of the patient and his parents had been performed previously 1. FISH studies indicated the deletion at EXT2 and IB1. The combined karyotype was 46,XY,del(11)(p13p11.2).ish del (11) 
Microsatellite analysis
Results are shown in Figure 4 Patient 1 Results comprised biparental alleles at markers D11S935 (ND, not deleted), D11S905 (ND), and D11S1355 (ND). Only a maternal allele was observed for markers D11S1393 (DEL, deleted), D11S554 (DEL), and D11S1344 (DEL). No informative result were obtained for D11S903 (NI, not informative), D11S2095 (NI), and D11S1326 (NI). This corresponds to a paternal deletion encompassing a maximum of 10. 
Discussion
P11pDS is a rare syndrome with less than 20 patients described in the literature today. We now report clinical, cytogenetic, FISH, and/or molecular findings in three nonrelated patients with the p11pDS, including two previously undescribed patients.
The two hallmarks of P11pDS are EXT and FPP. However, the age of manifestation of EXT is variable and FPP are a trait with variable penetrance.
1 Therefore, the absence of EXT and FPP in patient 2 was not necessarily contradictory with a diagnosis of P11pDS at the time the 11p deletion was identified, as the absence of multiple exostoses could be attributed to her young age at the time of diagnosis (34 months) and the absence of FPP could be explained by reduced penetrance. Clinical follow-up at the age of 7 years indeed showed the occurrence of multiple exostoses. Besides EXT and FPP a great variation in additional signs and symptoms have been described. Among these additional characteristics are structural brain abnormalities that have been added recently to the clinical spectrum after detailed clinical analysis of patients by CT and MRI. Also the only patient from this study for whom MRI data was available (patient 1) showed hypoplasia of the vermis and cerebellar hemispheres, similar to the cases described by Wuyts et al 3 and Yamamoto et al. 4 This suggests that these brain malformations may be under-recognised in previous reports in which no CT or MRI was performed and they may represent a more common feature of P11pDS. P11pDS patients demonstrate striking differences in intelligence, a subset having normal or near-normal intelligence and another subset (including patients 1 -3) showing severe to profound MR, strongly suggesting the presence of a major MR gene on proximal 11p. Most mentally retarded patients harbour deletions with more distal breakpoints, while the nonretarded individuals mostly harbour rather smaller deletions around the EXT2 gene. In contrast to EXT and FPP, the craniofacial abnormalities in PD11pDS are less well documented. Mild facial dysmorphism with brachycephaly and high forehead has been described in several patients, 1, 4, 8, 10, 17 but clear-cut craniofacial dysmorphism was only reported in a single patient (patient 3 of this report). In this study, we observed Myopia is a common condition with heterogeneous aetiology as it is found in monogenic disorders of dominant (e.g. Stickler syndrome, Marfan syndrome) and recessive (e.g. Cohen syndrome, homocystinuria) inheritance. In patient 1 high myopia is combined with eye movement disorders strabismus and nystagmus, which are frequently observed in patients with MR, including p11p11DS patients. 1, 8, 18 Since myopia can progress with advancing years and may even give rise to retinal detachment and, ultimately, blindness, periodical ophthalmologic check-ups are recommended in individuals with P11pDS and MR. The 11p11 region harbours several genes involved in the development of organs and structures affected in P11pDS patients, but with exception of EXT2 and ALX4, a clear correlation between heterozygous deletion of these genes and observed P11pDS phenotype has not yet been deducted. Mutations in some of these genes, such IB1, MYBPC3 or PEX16 have been associated with a disease phenotype. The human islet-brain-1 (IB1) or MAPK8IP1 gene is a DNA-binding transactivator of the glucose transporter GLUT2 and shows high expression in pancreas, brain, testis, retina, and prostate. 16 A single missense mutation in IB1 was reported to be associated with in a family with type II diabetes. 19 The effect of heterozygous inactivation of this gene is yet unknown, but in vitro and animal studies have indicated an important role of this gene in the hippocampus 20 humans. The gene product exhibits neurite outgrowthpromoting activity and may play a role in nervous system development and/or maintenance. Although positioned at 46.4 Mb and thus located outside the proximal MR critical region if previously published patients are considered, the NEGF2 gene was found deleted in the three patients, all with severe or profound MR, presented here. Therefore, NEGF2 may contribute to the MR spectrum in these patients. The P11pDS region also harbours the gene for lysosomal acid phosphatase (ACP2), a tartrate sensitive enzyme with ubiquitous expression. Animal studies have shown that a proportion of Acp À/À KO mice develop generalised seizures 24 making ACP2 an attractive candidate gene for the epilepsy that has been observed in P11pDS patients.
In conclusion, we have provided detailed clinical and molecular data that may lead to a better understanding of the underlying biological processes causing the P11pDS phenotype. However, further characterisation of P11pDS patients is required for identifying all the genes contributing to this syndrome.
